sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
lacosamide adroiq
extrovis eu ltd. - lakosamid - epilepsi - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
macrodex med natriumklorid 60 mg/ ml
meda - asker - dekstran 70 - infusjonsvæske, oppløsning - 60 mg/ ml
plasmodex 30 g/1000 ml
meda - asker - dekstran 60 - infusjonsvæske, oppløsning - 30 g/1000 ml
rescueflow 60 g/ l / 75 g/ l
oresund pharma aps - dekstran 70 / natriumklorid - infusjonsvæske, oppløsning - 60 g/ l / 75 g/ l
fortum 2 g
glaxosmithkline as - ceftazidimpentahydrat - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g
bricanyl 0.5 mg/ ml
astrazeneca - terbutalinsulfat - injeksjonsvæske, oppløsning - 0.5 mg/ ml
tears naturale 1 mg/ ml / 3 mg/ ml
alcon nordic a/s - dekstran 70 / hypromellose - Øyedråper, oppløsning i endosebeholder - 1 mg/ ml / 3 mg/ ml
reopro 2 mg/ ml
janssen biologics b.v - abciksimab - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml
reopro 2 mg/ ml
2care4 - abciksimab - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml